A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1798-1803

  Cagiannos, Ilias ^a,e   Karakiewicz, Pierre ^a   Eastham, James A ^a   Ohori, Makato ^a   Rabbani, Farhang ^a   Gerigk, Claudia ^a   Reuter, Victor ^a   Graefen, Markus ^b   Hammerer, Peter G ^b   Erbersdobler, Andreas ^b   Huland, Hartwig ^b   Kupelian, Patrick ^c   Klein, Eric ^c   Quinn, David I ^d   Henshall, Susan M ^d   Grygiel, John J ^d   Sutherland, Robert L ^d   Stricker, Phillip D ^d   Morash, Christopher G ^e   Scardino, Peter T ^a   Kattani, Michael W ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Forecasting; Lymph node excision; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CANCER STAGING; CLINICAL FEATURE; CLINICAL PROTOCOL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PATIENT SELECTION; PELVIS LYMPH NODE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 0141988872     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000091805.98960.13     Document Type: Article

References (20)

1. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am, 20: 713, 1993
2. Gervasi, L. A., Mata, J., Easley, J. D., Wilbanks, J. H., Seale-Hawkins, C., Carlton, C. E., Jr. et al: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol, 142: 332, 1989
3. Cheng, L., Zincke, H., Blute, M. L., Bergstralh, E. J., Scherer, B. and Bostwick, D. G.: Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer, 91: 66, 2001
4. Cadeddu, J. A., Partin, A. W., Epstein, J. I. and Walsh, P. C.: Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology, 50: 251, 1997
5. Brendler, C. B., Cleeve, L. K., Anderson, E. E. and Paulson, D. F.: Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit. J Urol, 124: 849, 1980
6. Donohue, R. E., Mani, J. H., Whitesel, J. A., Augspurger, R. R., Williams, G. and Fauver, H. E.: Intraoperative and early complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Urology, 35: 223, 1990
7. Campbell, S. C., Klein, E. A., Levin, H. S. and Piedmonte, M. R.: Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology, 46: 352, 1995
8. Soh, S., Kattan, M. W., Berkman, S., Wheeler, T. M. and Scardino, P. T.: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol, 157: 2212, 1997
9. Flanigan, R. C., McKay, T. C., Olson, M., Shankey, T. V., Pyle, J. and Waters, W. B.: Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology, 48: 428, 1996
10. Hinkle, G. H., Burgers, J. K., Neal, C. E., Texter, J. H., Kahn, D., Williams, R. D. et al: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer, 83: 739, 1998
11. Bluestein, D. L., Bostwick, D. G., Bergstralh, E. J. and Oesterling, J. E.: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol, 151: 1315, 1994
12. Bishoff, J. T., Reyes, A., Thompson, I. M., Harris, M. J., St. Clair, S. R., Gomella, L. et al: Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology, 45: 270, 1995
13. Narayan, P., Fournier, G., Gajendran, V., Leidich, R., Lo, R., Wolf, J. S., Jr. et al: Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology, 44: 519, 1994
14. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
15. Conrad, S., Graefen, M., Pichlmeier, U., Henke, R.-P., Erbersdobler, A., Hammerer, P. G. et al: Prospective validation of an algorithm with systemic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol, 167: 521, 2002
16. Haese, A., Epstein, J. I., Huland, H. and Partin, A. W.: Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer, 95: 1016, 2002
17. Harrell, F. E., Jr.: Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis (Springer Series in Statistics). New York: Springer-Verlag, p. 568, 2001
18. McLaughlin, A. P., Saltzstein, S. L., McCullough, D. L. and Gittes, R. F.: Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J Urol, 115: 89, 1976
19. Golimbu, M., Morales, P., Al-Askari, S. and Brown, J.: Extended pelvic lymphadenectomy for prostatic cancer. J Urol, 121: 617, 1979
20. Heidenreich, A., Varga, Z. and von Knobloch, R.: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol, 167: 1681, 2002